Stockscreener 앱 받기
5.40
0.19%
0.01
시간 외 거래:
5.38
-0.02
-0.37%
전일 마감가:
$5.39
열려 있는:
$5.39
하루 거래량:
1.04M
Relative Volume:
0.88
시가총액:
$1.21B
수익:
$596.48M
순이익/손실:
$123.72M
주가수익비율:
9.8468
EPS:
0.5484
순현금흐름:
$106.59M
1주 성능:
-1.10%
1개월 성능:
-0.74%
6개월 성능:
+30.43%
1년 성능:
+47.14%
1일 변동 폭
$5.38
$5.42
1주일 범위
$5.38
$5.49
52주 변동 폭
$2.37
$5.72
큐어백 Stock (CVAC) Company Profile
CVAC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CVAC
Curevac N V
|
5.40 | 1.23B | 596.48M | 123.72M | 106.59M | 0.5484 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
큐어백 Stock (CVAC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-13 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-04-25 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-06-08 | 개시 | SVB Securities | Outperform |
| 2023-01-19 | 업그레이드 | UBS | Neutral → Buy |
| 2023-01-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-01-21 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-01-18 | 개시 | JMP Securities | Mkt Outperform |
| 2021-10-22 | 개시 | Deutsche Bank | Hold |
| 2021-06-17 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-04-26 | 재개 | Credit Suisse | Underperform |
| 2021-04-26 | 개시 | Guggenheim | Neutral |
| 2020-12-10 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2020-09-08 | 개시 | BofA Securities | Buy |
| 2020-09-08 | 개시 | Credit Suisse | Neutral |
| 2020-09-08 | 개시 | Jefferies | Hold |
모두보기
큐어백 주식(CVAC)의 최신 뉴스
CureVac N.V.Finanzen.net - Finanzen.net
CureVac N.V. Stock Analysis and ForecastStrong return on assets - PrintWeekIndia
Is CureVac N.V. a good long term investmentExceptional stock performance - Autocar Professional
What drives CureVac N.V. stock priceExtraordinary market timing - jammulinksnews.com
What analysts say about CureVac N.V. stockConsistent wealth multiplication - jammulinksnews.com
CureVac: Pipeline pruning’s nasty effect - MarketScreener
CureVac N.V. (CVAC) Has Gained Over 16% In One Month. Here Is Why - Insider Monkey
Tesla chief Elon Musk teams up with Covid-19 player CureVac to build ‘RNA microfactories’ - Endpoints News
CureVac Announces Key Resolutions from Annual Shareholders Meeting - TipRanks
CureVac (CVAC) Downgraded by UBS as Acquisition Looms | CVAC Stock News - GuruFocus
CureVac Announces Key Appointments and Auditor Reappointment at Annual Meeting - TipRanks
CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech - Zacks Investment Research
Private-Public Deal Momentum Grows, Yet Megamergers Stay Elusive - Investing.com
BioNTech SE Announces Acquisition of CureVac N.V. - TipRanks
Germany: BioNTech to acquire CureVac in all-stock transaction - Investors in Healthcare
BioNTech to Acquire CureVac in Strategic Move - TipRanks
CureVac agrees to pay Biontech termination fee Of $43.8 mln under specified circumstances - MarketScreener
5 Stocks To Ride The German Market RallyCureVac (NASDAQ:CVAC), BioNTech (NASDAQ:BNTX) - Benzinga
BioNTech to Acquire CureVac in US$1.25 Billion All-Stock Transaction - Global Legal Chronicle
There's No Escaping CureVac N.V.'s (NASDAQ:CVAC) Muted Revenues Despite A 50% Share Price Rise - simplywall.st
CureVac’s SWOT analysis: mRNA pioneer’s stock faces pivotal year ahead By Investing.com - Investing.com Nigeria
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVAC, KNW, SOAR, HLGN on Behalf of - Bluefield Daily Telegraph
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVAC, KNW, SOAR, HLGN on Behalf of Shareholders - TradingView
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BioNTech CureVac Acquisition Boosts Cancer Drug Pipeline - Industry Leaders Magazine
CureVac (CVAC) Receives Downgrade and Price Target Reduction fro - GuruFocus
BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer - GlobeNewswire
Jefferies cuts CureVac stock rating to hold on BioNTech acquisition By Investing.com - Investing.com UK
BioNTech: Oddo BHF raises target price - marketscreener.com
BioNTech to buy CureVac in USD 1.25 billion all-stock deal - Medical Dialogues
CureVac Stock: BioNTech's Billion-Dollar Takeover Bid - sharewise
BioNTech (BNTX) to Acquire CureVac in $1.25 Billion All-Stock De - GuruFocus
CureVac (CVAC) Downgraded by Jefferies Analyst After BioNTech Acquisition Agreement | CVAC Stock News - GuruFocus
BioNTech Announces Strategic Transaction to Acquire CureVac in P - GuruFocus
BioNTech Announces Strategic Acquisition of CureVac - TipRanks
Biontech’s $1.25B Curevac buyout removes mRNA lawsuit uncertainty - BioWorld MedTech
BioNTech to Acquire CureVac in $1.25B Deal - USA Herald
BioNTech's Acquisition Of CureVac Brings Complementary Method To Target Cancer (BNTX) - Seeking Alpha
5 Firms Guide $1.25B BioNTech, CureVac Oncology Deal - Law360
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVAC, SOAR, MTWO on Behalf of Shareholders - MarketScreener
BioNTech to acquire CureVac in $1.25 billion all-stock deal By Investing.com - Investing.com South Africa
BioNTech to Acquire CureVac to Expand mRNA Cancer Therapies - N24.com.tr
BioNTech buys mRNA, courtroom rival CureVac in all-stock deal - BioPharma Dive
Watkins Advises on BioNTech’s US$1.25 Billion Acquisition of CureVac - Latham & Watkins LLP
BioNTech Buys CureVac For $1.25 Billion In Stock Deal - Finimize
M&A News: BioNTech (BNTX) Acquires CureVac in $1.25 Billion Deal - TipRanks
CureVac Stock Soars on BioNTech Buyout - Schaeffer's Investment Research
BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal - Benzinga
큐어백 (CVAC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
0.17%
자본화:
|
볼륨(24시간):